已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma

无容量 医学 易普利姆玛 阿西替尼 彭布罗利珠单抗 舒尼替尼 肾细胞癌 内科学 肿瘤科 不利影响 癌症 免疫疗法
作者
Alan Chan,Carolyn Dang,J. Wiśniewski,Xiuhua Weng,Edward Hynson,Lixian Zhong,Leslie Wilson
出处
期刊:American Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:45 (2): 66-73 被引量:7
标识
DOI:10.1097/coc.0000000000000884
摘要

The US Food and Drug Administration (FDA) approved nivolumab-ipilimumab and pembrolizumab-axitinib as first-line treatments for metastatic, clear-cell, renal cell carcinoma (mRCC) based on results from CheckMate 214 and KEYNOTE-426. Our objective was to compare the adjusted, lifetime cost-effectiveness between nivolumab-ipilimumab, pembrolizumab-axitinib, and sunitinib for patients with mRCC.A 3-state Markov model was developed comparing nivolumab-ipilimumab and pembrolizumab-axitinib to each other and sunitinib, over a 20-year lifetime horizon from a US medical center perspective. The clinical outcomes of nivolumab-ipilimumab and pembrolizumab-axitinib were compared using matching-adjusted indirect comparison. Costs of drug treatment, adverse events, and utilities associated with different health states and adverse events were determined using national sources and published literature. Our outcome was incremental cost-effectiveness ratio (ICER) using quality-adjusted life years (QALY). One-way and probabilistic sensitivity analyses were conducted.Nivolumab-ipilimumab was the most cost-effective option in the base case analysis with an ICER of $34,190/QALY compared with sunitinib, while the pembrolizumab-axitinib ICER was dominated by nivolumab-ipilimumab and was not cost-effective (ICER=$12,630,828/QALY) compared with sunitinib. The mean total costs per patient for the nivolumab-ipilimumab and pembrolizumab-axitinib arms were $284,683 and $457,769, respectively, compared with sunitinib at $241,656. QALY was longer for nivolumab-ipilimumab (3.23 QALY) than for adjusted pembrolizumab-axitinib (1.99 QALY), which was longer than sunitinib's (1.98 QALY). These results were most sensitive to treatment cost in both groups, but plausible changes did not alter the conclusions.The base case scenario indicated that nivolumab-ipilimumab was the most cost-effective treatment option for mRCC compared with pembrolizumab-axitinib and sunitinib.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
千纸鹤完成签到 ,获得积分10
2秒前
3秒前
5秒前
充电宝应助甜蜜邑采纳,获得10
6秒前
100完成签到,获得积分10
9秒前
10秒前
HB完成签到,获得积分10
12秒前
怕黑的路人完成签到,获得积分10
14秒前
HH完成签到,获得积分10
15秒前
CipherSage应助蟹治猿采纳,获得10
17秒前
川荣李奈完成签到 ,获得积分10
18秒前
雪生在无人荒野完成签到,获得积分10
19秒前
动听的谷秋完成签到 ,获得积分10
19秒前
寒冷的青筠完成签到 ,获得积分10
20秒前
陈博士关注了科研通微信公众号
20秒前
朴实剑通完成签到,获得积分10
22秒前
火星上的柏柳完成签到 ,获得积分10
23秒前
luocan完成签到,获得积分10
24秒前
想法文章的菜鸟完成签到,获得积分10
25秒前
26秒前
星辰大海应助科研通管家采纳,获得10
27秒前
桐桐应助科研通管家采纳,获得10
27秒前
JamesPei应助科研通管家采纳,获得10
27秒前
风清扬完成签到,获得积分10
27秒前
27秒前
科研通AI2S应助科研通管家采纳,获得10
27秒前
小马甲应助科研通管家采纳,获得10
27秒前
27秒前
储物间完成签到,获得积分10
27秒前
非了个凡完成签到 ,获得积分10
30秒前
31秒前
秀丽奎完成签到 ,获得积分10
33秒前
充电宝应助HH采纳,获得10
35秒前
KONOHA完成签到,获得积分10
36秒前
橙子完成签到,获得积分10
36秒前
花深粥发布了新的文献求助10
36秒前
每文完成签到,获得积分10
37秒前
38秒前
火翟丰丰山心完成签到,获得积分10
39秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Comprehensive Methanol Science Production, Applications, and Emerging Technologies 1200
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
By R. Scott Kretchmar - Practical Philosophy of Sport and Physical Activity - 2nd (second) Edition: 2nd (second) Edition 666
Electrochemistry: Volume 17 600
Physical Chemistry: How Chemistry Works 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4944455
求助须知:如何正确求助?哪些是违规求助? 4209377
关于积分的说明 13085135
捐赠科研通 3989004
什么是DOI,文献DOI怎么找? 2183965
邀请新用户注册赠送积分活动 1199322
关于科研通互助平台的介绍 1112234